Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643569 | 0.96 | DDB1 (0.59) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL26641530 | 0.96 | DDB1 (0.59) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL23301226 | 0.93 | DDB1 (0.67) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL21876964 | 0.93 | DDB1 (0.67) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL24480733 | 0.90 | GPR119 (0.62) | DDB1CRBNGPR119 | |
| SCHEMBL31607945 | 0.89 | DDB1 (0.58) | DDB1CRBNGPR119MAPT | |
| SCHEMBL30643603 | 0.88 | CRBN (0.61) | DDB1CRBNGPR119MAPT | |
| SCHEMBL26641267 | 0.88 | CRBN (0.61) | DDB1CRBNGPR119MAPT | |
| SCHEMBL31726711 | 0.87 | DDB1 (0.60) | DDB1CRBNGPR119 | |
| SCHEMBL29680886 | 0.87 | DDB1 (0.60) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20240374588-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| WO-2024209044-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374588-A1 | IRAK4 PROTACS | IRAK4, IRAK2, IRAK3 | DDB1 728/4885CRBN 99/4885GPR119 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.